ArticleFrontiers in medicine2026
Effect of intravenous immunoglobulin combined with azithromycin sequential therapy on clinical outcomes and immune response in children with
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Novel Nomogram Integrating Clinical, Radiological, and Immunological Indicators for Early Prediction of SevereJournal of inflammation research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Methods: This single-center retrospective, non-randomized cohort study included 140 children diagnosed with MPP between January 2020 and February 2022. Patients received either azithromycin sequential therapy alone (control group, Results: The total effective rate was higher in the IVIG group than in the control group (97.14% vs. 84.29%, Conclusion: Adjunctive IVIG combined with azithromycin was associated with improved clinical and laboratory outcomes in children with MPP without increasing adverse events. Findings should be interpreted cautiously due to the retrospective design and potential residual confounding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.